A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor-positive (ER+)/HER2-negative (HER2-) breast cancer

被引：0
|
作者：
Borges, Virginia F.
Chan, Arlene
Lin, Nancy U.
Tonda, Margaret Eleanor
Shilkrut, Mark
Alemany, Carlos A.
机构：
[1] Univ Colorado, Canc Ctr, Aurora, CO USA
[2] Breast Canc Res Ctr WA, Nedlands, Australia
[3] Curtin Univ, Nedlands, Australia
[4] Dana Farber Canc Inst, Boston, MA USA
[5] Olema Oncol, San Francisco, CA USA
[6] AdventHlth Orlando, Orlando, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1127
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer
    Basaran, Gul A.
    Twelves, Chris
    Dieras, Veronique
    Cortes, Javier
    Awada, Ahmad
    CANCER TREATMENT REVIEWS, 2018, 63 : 144 - 155
  • [42] H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (-) breast cancer (BC)
    Hamilton, Erika P.
    Pluard, Timothy J.
    Wang, Judy S.
    Morikawa, Aki
    Johnston, Stephen R. D.
    Dees, Elizabeth Claire
    Vaklavas, Christos
    Armstrong, Anne C.
    Munster, Pamela N.
    Unni, Nisha
    Wright, Gail Lynn Shaw
    Kayali, Fadi
    Song, Tingting
    Rong, Yuanxin
    Yamaguchi, Kohei
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study
    Ciruelos, E. M.
    Hamilton, E. P.
    Kim, S-B.
    Im, Y-H.
    Solis, E. Segui
    Saenz, J. A. Garcia
    Di Sanzo, A.
    Lizarbe, M. Dominguez
    Wasserman, T.
    Theall, K. P.
    Ibrahim, N. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S370 - S370
  • [44] Alpelisib plus letrozole in estrogen receptor-Positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC): Safety and preliminary efficacy analysis from a phase 1b trial
    Juric, Dejan
    Goncalves, Anthony
    Hamilton, Erika
    Boni, Valentina
    Mayer, Ingrid A.
    Turri, Sabine
    Wang, Yingbo
    Vogl, Florian D.
    Sellami, Dalila
    Campone, Mario
    CANCER RESEARCH, 2018, 78 (04)
  • [45] Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    Kahraman, Seda
    Erul, Enes
    Seyyar, Mustafa
    Gumusay, Ozge
    Bayram, Ertugrul
    Demirel, Burcin Cakan
    Acar, Omer
    Aksoy, Sercan
    Baytemur, Naziyet Kose
    Sahin, Elif
    Cabuk, Devrim
    Basaran, Gul
    Paydas, Semra
    Yaren, Arzu
    Guven, Deniz Can
    Erdogan, Atike Pinar
    Demirci, Umut
    Yasar, Alper
    Bayoglu, Ibrahim Vedat
    Hizal, Mutlu
    Gulbagci, Burcu
    Paksoy, Nail
    Davarci, Sena Ece
    Yilmaz, Funda
    Dogan, Ozlem
    Orhan, Sibel Oyucu
    Kayikcioglu, Erkan
    Aytac, Ali
    Keskinkilic, Merve
    Mocan, Eda Eylemer
    Unal, Olcun Umit
    Aydin, Esra
    Yucel, Hakan
    Isik, Deniz
    Eren, Onder
    Uluc, Basak Oyan
    Ozcelik, Melike
    Hacibekiroglu, Ilhan
    Aydiner, Adnan
    Demir, Hacer
    Oksuzoglu, Berna
    Cilbir, Ebru
    Cubukcu, Erdem
    Cetin, Bulent
    Oktay, Esin
    Erol, Cihan
    Okutur, Sadi Kerem
    Yildirim, Nilgun
    Alkan, Ali
    Selcukbiricik, Fatih
    FUTURE ONCOLOGY, 2023, : 727 - 736
  • [46] Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer
    Hunter, Natasha B.
    Peterson, Lanell M.
    Specht, Jennifer M.
    Mankoff, David A.
    Muzi, Mark
    Chen, Delphine L.
    Gwin, William R.
    Vinayak, Shaveta
    Davidson, Nancy E.
    Linden, Hannah M.
    BREAST CANCER RESEARCH, 2025, 27 (01)
  • [47] Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) in MONALEESA-2
    Sonke, G. S.
    Hart, L. L.
    Campone, M.
    Erdkamp, F.
    Janni, W.
    Verma, S.
    Villanueva, C.
    Jakobsen, E.
    Alba, E.
    Wist, E.
    Favret, A. M.
    Bachelot, T.
    Hegg, R.
    Wheatley-Price, P.
    Souami, F.
    Sutradhar, S.
    Miller, M.
    Germa, C.
    Burris, H. A.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S1 - S2
  • [48] Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
    Rebecca A. Shatsky
    Hemali Batra-Sharma
    Teresa Helsten
    Richard B. Schwab
    Emily I. Pittman
    Minya Pu
    Elizabeth Weihe
    Emanuela M. Ghia
    Laura Z. Rassenti
    Alfredo Molinolo
    Betty Cabrera
    James B. Breitmeyer
    George F. Widhopf II
    Karen Messer
    Catriona Jamieson
    Thomas J. Kipps
    Barbara A. Parker
    Breast Cancer Research, 26
  • [49] FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    Charlab, Rosane
    Chen, Wei
    Palmby, Todd
    Tilley, Amy
    Zirkelbach, Jeanne Fourie
    Yu, Jingyu
    Liu, Qi
    Zhao, Liang
    Crich, Joyce
    Chen, Xiao Hong
    Hughes, Minerva
    Bloomquist, Erik
    Tang, Shenghui
    Sridhara, Rajeshwari
    Kluetz, Paul G.
    Kim, Geoffrey
    Ibrahim, Amna
    Pazdur, Richard
    Cortazar, Patricia
    CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4760 - 4766
  • [50] H3B-6545+palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (-) breast cancer (BC)
    Johnston, Stephen R. D.
    Pluard, Timothy J.
    Wang, Judy S.
    Hamilton, Erika P.
    Song, Tingting
    Rong, Yuanxin
    Yamaguchi, Kohei
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345